IL-13 Targeting Biologics for the Treatment of Atopic Dermatitis - Episode 8
Efficacy Data With IL-13 Targeting Agents in Atopic Dermatitis
Published on:
Panelists provide an overview of the latest efficacy and safety data for IL-13–targeting therapies in atopic dermatitis (AD), including recently presented data on dupilumab, lebrikizumab, and tralokinumab, focusing on their effectiveness in symptom reduction and safety profiles across patient populations.
Video content above is prompted by the following:
- Please give an overview of latest efficacy and safety data with IL-13–targeting therapies in AD, including recently presented data.
- Dupilumab
- Lebrikizumab
- Tralokinumab
